| scholarly article | Q13442814 |
| P50 | author | Theodore C Pierson | Q59939112 |
| Leslie Goo | Q66680234 | ||
| P2093 | author name string | Laura A. VanBlargan | |
| P2860 | cites work | Selection forces and constraints on retroviral sequence variation. | Q55239815 |
| Neutralization of poliovirus by a monoclonal antibody: Kinetics and stoichiometry | Q70151362 | ||
| A proteomics approach for the identification and cloning of monoclonal antibodies from serum | Q83739906 | ||
| Few and far between: how HIV may be evading antibody avidity | Q21090507 | ||
| The mannose receptor mediates dengue virus infection of macrophages | Q21090526 | ||
| Origins of HIV and the AIDS Pandemic | Q22242661 | ||
| Biology of Zika Virus Infection in Human Skin Cells | Q22330706 | ||
| Mechanism and significance of cell type-dependent neutralization of flaviviruses | Q23032973 | ||
| The 3.8 Å resolution cryo-EM structure of Zika virus | Q23680595 | ||
| Structure of the thermally stable Zika virus | Q24082710 | ||
| Factors shaping the adaptive landscape for arboviruses: implications for the emergence of disease | Q24273397 | ||
| Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes | Q24289053 | ||
| Phylogeny of the Genus Flavivirus | Q24471099 | ||
| Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses | Q24536024 | ||
| Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection | Q24538985 | ||
| Viral mutation rates | Q24611162 | ||
| The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry | Q24620686 | ||
| The global distribution and burden of dengue | Q24628768 | ||
| Increasing the potency and breadth of an HIV antibody by using structure-based rational design | Q24631510 | ||
| Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21) | Q24633690 | ||
| Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals | Q24635002 | ||
| Rapid cloning of high-affinity human monoclonal antibodies against influenza virus | Q24644672 | ||
| The Phosphatidylserine and Phosphatidylethanolamine Receptor CD300a Binds Dengue Virus and Enhances Infection | Q24672470 | ||
| DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells | Q24673466 | ||
| Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer | Q27680497 | ||
| The structural basis for serotype-specific neutralization of dengue virus by a human antibody | Q27681306 | ||
| Proof of principle for epitope-focused vaccine design | Q27681593 | ||
| Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike | Q27683540 | ||
| Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers | Q27683553 | ||
| Recognition determinants of broadly neutralizing human antibodies against dengue viruses | Q27697333 | ||
| Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G | Q27704710 | ||
| The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution | Q27730234 | ||
| Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 | ||
| Human antibody-Fc receptor interactions illuminated by crystal structures | Q28252414 | ||
| Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env | Q28256508 | ||
| Class-switch recombination: interplay of transcription, DNA deamination and DNA repair | Q28269740 | ||
| The antigenic structure of the HIV gp120 envelope glycoprotein | Q28274698 | ||
| Cross-reacting antibodies enhance dengue virus infection in humans | Q28281588 | ||
| Dengue Virus Ensures Its Fusion in Late Endosomes Using Compartment-Specific Lipids | Q28475709 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection | Q29547852 | ||
| Viral dynamics in human immunodeficiency virus type 1 infection | Q29547908 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| A structural perspective of the flavivirus life cycle | Q29616269 | ||
| Mapping the antigenic and genetic evolution of influenza virus | Q29617255 | ||
| Distribution and three-dimensional structure of AIDS virus envelope spikes | Q29617562 | ||
| Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate | Q29618060 | ||
| Structural basis of West Nile virus neutralization by a therapeutic antibody | Q29618168 | ||
| Neutralization and antibody-dependent enhancement of dengue viruses | Q29618172 | ||
| Structure of West Nile Virus | Q29618173 | ||
| Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica | Q29618177 | ||
| Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM | Q29618178 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites | Q29619017 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever | Q29619530 | ||
| Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase | Q29619994 | ||
| Evidence That Maternal Dengue Antibodies Are Important in the Development of Dengue Hemorrhagic Fever in Infants | Q29620637 | ||
| Evolutionary and immunological implications of contemporary HIV-1 variation. | Q30329205 | ||
| Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements | Q30364187 | ||
| Implications of HIV diversity for the HIV-1 pandemic | Q30422902 | ||
| Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. | Q33283730 | ||
| A method for identification of HIV gp140 binding memory B cells in human blood | Q33394829 | ||
| Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production | Q24676570 | ||
| Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention | Q24684689 | ||
| Structure of dengue virus: implications for flavivirus organization, maturation, and fusion | Q24736810 | ||
| Structural basis of potent Zika–dengue virus antibody cross-neutralization | Q24740325 | ||
| GlyProt: in silico glycosylation of proteins | Q24812315 | ||
| The HIV glycan shield as a target for broadly neutralizing antibodies | Q26786540 | ||
| Degrees of maturity: the complex structure and biology of flaviviruses | Q26824712 | ||
| HIV entry: a game of hide-and-fuse? | Q26824979 | ||
| Structural insights on the role of antibodies in HIV-1 vaccine and therapy | Q26829461 | ||
| A Blueprint for HIV Vaccine Discovery | Q26829865 | ||
| The molecular basis ofHIVentry | Q26863686 | ||
| The Antibody Response against HIV-1 | Q27000889 | ||
| Influenza virus hemagglutinin stalk-based antibodies and vaccines | Q27001190 | ||
| Zika virus: history of a newly emerging arbovirus | Q27011701 | ||
| The role of matrix in HIV-1 envelope glycoprotein incorporation | Q27023106 | ||
| HIV-1 Reverse Transcription | Q27023387 | ||
| HIV broadly neutralizing antibody targets | Q27026662 | ||
| Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification | Q27315772 | ||
| Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells | Q27318246 | ||
| Assembly and Maturation of the Flavivirus Kunjin Virus Appear To Occur in the Rough Endoplasmic Reticulum and along the Secretory Pathway, Respectively | Q27469877 | ||
| Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells | Q27469935 | ||
| West Nile Virus Discriminates between DC-SIGN and DC-SIGNR for Cellular Attachment and Infection | Q27472821 | ||
| Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through Fc Receptor-Dependent and -Independent Mechanisms | Q27472823 | ||
| Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum | Q27472959 | ||
| Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus | Q27473186 | ||
| Isolation and Characterization of Human Monoclonal Antibodies from Individuals Infected with West Nile Virus | Q27473288 | ||
| Intracellular Assembly and Secretion of Recombinant Subviral Particles from Tick-Borne Encephalitis Virus | Q27473375 | ||
| Structures of immature flavivirus particles | Q27477478 | ||
| West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody | Q27477479 | ||
| Cryptic Properties of a Cluster of Dominant Flavivirus Cross-Reactive Antigenic Sites | Q27477542 | ||
| Broad and potent neutralization of HIV-1 by a gp41-specific human antibody | Q27675131 | ||
| Cryo-EM structure of the mature dengue virus at 3.5-Å resolution | Q27675507 | ||
| Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth | Q27676728 | ||
| Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody | Q27676931 | ||
| Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody | Q27677011 | ||
| Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 | ||
| Dengue structure differs at the temperatures of its human and mosquito hosts | Q27677270 | ||
| Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 | Q27678312 | ||
| Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies | Q27679353 | ||
| Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer | Q27680496 | ||
| Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein | Q27477718 | ||
| Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form | Q27480299 | ||
| Structure of Immature West Nile Virus | Q27480359 | ||
| Proteolytic activation of tick-borne encephalitis virus by furin | Q27480892 | ||
| The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein | Q27481009 | ||
| Probing the Flavivirus Membrane Fusion Mechanism by Using Monoclonal Antibodies | Q27481499 | ||
| Induction of Epitope-Specific Neutralizing Antibodies against West Nile Virus | Q27484980 | ||
| Epitope Determinants of a Chimpanzee Dengue Virus Type 4 (DENV-4)-Neutralizing Antibody and Protection against DENV-4 Challenge in Mice and Rhesus Monkeys by Passively Transferred Humanized Antibody | Q27485025 | ||
| Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes | Q27485031 | ||
| Maturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated Neutralization | Q27485890 | ||
| Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II | Q27486409 | ||
| Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus | Q27486788 | ||
| The structural immunology of antibody protection against West Nile virus | Q27487955 | ||
| The Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus Infection | Q27488224 | ||
| Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens | Q27488243 | ||
| Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development | Q27488364 | ||
| A Therapeutic Antibody against West Nile Virus Neutralizes Infection by Blocking Fusion within Endosomes | Q27488367 | ||
| Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step | Q27488791 | ||
| Impact of Quaternary Organization on the Antigenic Structure of the Tick-Borne Encephalitis Virus Envelope Glycoprotein E | Q27489515 | ||
| Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody | Q27489654 | ||
| Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody | Q27490283 | ||
| Complement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile Virus | Q27490423 | ||
| The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 | Q27491317 | ||
| Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus | Q27644501 | ||
| Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins | Q27649830 | ||
| The flavivirus precursor membrane-envelope protein complex: structure and maturation | Q27650164 | ||
| Structure of the immature dengue virus at low pH primes proteolytic maturation | Q27650165 | ||
| Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | Q27663293 | ||
| Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354 | Q27665151 | ||
| Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding | Q27670829 | ||
| Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing | Q27671696 | ||
| Structural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic Epitope | Q27674417 | ||
| A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield | Q27675032 | ||
| Taxonomy of the virus family Flaviviridae | Q35616799 | ||
| Antigenic structure of flavivirus proteins | Q35616815 | ||
| Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants | Q35627714 | ||
| A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus | Q35654743 | ||
| Strategies to guide the antibody affinity maturation process | Q35685300 | ||
| The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection | Q35686970 | ||
| A germinal center–independent pathway generates unswitched memory B cells early in the primary response | Q35825984 | ||
| HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes | Q35826271 | ||
| Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H | Q35847453 | ||
| Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors | Q35857221 | ||
| Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination | Q35878770 | ||
| Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection | Q35974269 | ||
| Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions | Q35982791 | ||
| Antigen-specific memory B cell development | Q36072438 | ||
| Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein | Q36131738 | ||
| A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies | Q36205859 | ||
| High affinity germinal center B cells are actively selected into the plasma cell compartment. | Q36228042 | ||
| Yellow fever vaccine | Q36238729 | ||
| Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing | Q36245225 | ||
| A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection | Q36276543 | ||
| DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers | Q36352752 | ||
| CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function | Q36368291 | ||
| Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells | Q36368917 | ||
| Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape | Q36388754 | ||
| Flavivirus membrane fusion | Q36590420 | ||
| A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial | Q36607295 | ||
| The impact of glycosylation on the biological function and structure of human immunoglobulins. | Q36618276 | ||
| Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature | Q36634400 | ||
| Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response | Q36637360 | ||
| Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins | Q36637389 | ||
| Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody | Q36642588 | ||
| Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses | Q36693991 | ||
| Virus glycosylation: role in virulence and immune interactions | Q36775963 | ||
| Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways | Q33504599 | ||
| Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection | Q33504604 | ||
| Interactions of protein antigens with antibodies | Q33594252 | ||
| Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. | Q33737656 | ||
| Early development of broadly neutralizing antibodies in HIV-1-infected infants | Q33764917 | ||
| The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response | Q33886727 | ||
| HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities | Q33900395 | ||
| Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. | Q33916640 | ||
| The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin | Q33943327 | ||
| In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection | Q33945441 | ||
| A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus | Q33954392 | ||
| A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial | Q33988937 | ||
| Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses | Q34023249 | ||
| A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals | Q34047445 | ||
| Particle conformation regulates antibody access to a conserved GII.4 norovirus blockade epitope | Q34059136 | ||
| Convergent antibody signatures in human dengue | Q34060276 | ||
| Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon. | Q34063398 | ||
| Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies | Q34114798 | ||
| Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. | Q34120070 | ||
| Analysis of Epitopes on Dengue Virus Envelope Protein Recognized by Monoclonal Antibodies and Polyclonal Human Sera by a High Throughput Assay | Q34123956 | ||
| A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virus | Q34132718 | ||
| Diversity considerations in HIV-1 vaccine selection | Q34136023 | ||
| Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity | Q34204325 | ||
| The antiviral activity of antibodies in vitro and in vivo. | Q34212487 | ||
| Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition | Q34261496 | ||
| Germinal center selection and the development of memory B and plasma cells | Q34268133 | ||
| Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes | Q34270980 | ||
| A model for neutralization of viruses based on antibody coating of the virion surface | Q34302544 | ||
| The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. | Q34306883 | ||
| Broadly neutralizing antiviral antibodies | Q34323311 | ||
| Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity | Q34352416 | ||
| A stepwise epigenetic process controls immunoglobulin allelic exclusion | Q34354933 | ||
| The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein | Q34386384 | ||
| Norovirus GII.4 strain antigenic variation | Q34457831 | ||
| Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments | Q36779926 | ||
| Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity | Q36797342 | ||
| Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics | Q36846290 | ||
| Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies | Q36884458 | ||
| Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo | Q36931818 | ||
| A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection | Q37012203 | ||
| Human monoclonal antibodies by immortalization of memory B cells | Q37026347 | ||
| Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals | Q37033400 | ||
| Estimating the stoichiometry of human immunodeficiency virus entry | Q37051613 | ||
| HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant | Q37059216 | ||
| Cellular proteins detected in HIV-1. | Q37081238 | ||
| Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection | Q37104756 | ||
| Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection | Q37123259 | ||
| Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. | Q37183108 | ||
| Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch | Q37213491 | ||
| The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states | Q37336735 | ||
| Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins | Q37395095 | ||
| Glycosylation as a strategy to improve antibody-based therapeutics | Q37402407 | ||
| The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity | Q37448171 | ||
| High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination | Q37471315 | ||
| West nile virus in the United States - a historical perspective | Q37666773 | ||
| Structure and function of immunoglobulins | Q37696721 | ||
| Correlates of protection induced by vaccination | Q37750121 | ||
| Viva la revolución: rethinking influenza a virus antigenic drift | Q37950365 | ||
| Clonal and cellular dynamics in germinal centers | Q38200435 | ||
| Type I and type II Fc receptors regulate innate and adaptive immunity | Q38232105 | ||
| Antibody B cell responses in HIV-1 infection | Q38252874 | ||
| The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance | Q38680892 | ||
| Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers | Q39001126 | ||
| Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature | Q39444247 | ||
| A multi-hit model for the neutralization of animal viruses | Q39471003 | ||
| Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer | Q39949085 | ||
| Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera | Q40298293 | ||
| Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection | Q40302703 | ||
| The Role of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in Virus Infection | Q40433970 | ||
| Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus | Q40441111 | ||
| The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. | Q40468552 | ||
| A recombinant Fab neutralizes dengue virus in vitro | Q40637673 | ||
| Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus | Q40676556 | ||
| Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. | Q40686966 | ||
| Mutational Analysis of Measles Virus Suggests Constraints on Antigenic Variation of the Glycoproteins | Q41205403 | ||
| A new mechanism for the neutralization of enveloped viruses by antiviral antibody | Q41352659 | ||
| Quantitative relationships between an influenza virus and neutralizing antibody | Q41460696 | ||
| Idiopathic Fanconi syndrome with progressive renal failure: a case report and discussion | Q41569988 | ||
| Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody | Q41967451 | ||
| Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. | Q42166543 | ||
| Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy | Q42288273 | ||
| The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein | Q42980684 | ||
| Studies on the glycosylation of flavivirus E proteins and the role of carbohydrate in antigenic structure | Q42988896 | ||
| Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus | Q42988971 | ||
| pH-dependent fusion between the flavivirus West Nile and liposomal model membranes | Q42994286 | ||
| Membrane fusion activity of tick-borne encephalitis virus and recombinant subviral particles in a liposomal model system | Q42997821 | ||
| Antibody-induced conformational changes result in enhanced avidity of antibodies to different antigenic sites on the tick-borne encephalitis virus glycoprotein | Q43030495 | ||
| Dengue virus envelope protein domain I/II hinge: a key target for dengue virus vaccine design? | Q43038900 | ||
| Multiple layers of B cell memory with different effector functions | Q43255281 | ||
| Monoclonal antibodies which recognize the acidic configuration of the rabies glycoprotein at the surface of the virion can be neutralizing | Q44771925 | ||
| Reversibility of the reaction between polio-virus and neutralizing antibody of rabbit origin | Q45717926 | ||
| A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus | Q45720362 | ||
| Mechanisms of Rabies Virus Neutralization | Q45786973 | ||
| Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. | Q45849314 | ||
| Inhibition of inducible nitric oxide synthase lowers the cochlear damage by lipopolysaccharide in guinea pigs | Q46176015 | ||
| Fc receptor but not complement binding is important in antibody protection against HIV. | Q46545827 | ||
| Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning | Q46683819 | ||
| HIV-1 nomenclature proposal | Q48750867 | ||
| Humoral Immunity Due to Long-Lived Plasma Cells | Q52040025 | ||
| Lifetime of plasma cells in the bone marrow | Q52042101 | ||
| An analysis of the inactivation of MS2 bacteriophage with antiserum | Q54303672 | ||
| Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface | Q34473958 | ||
| The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. | Q34481429 | ||
| Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody | Q34526404 | ||
| Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones | Q34593818 | ||
| Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination | Q34594111 | ||
| Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. | Q34607919 | ||
| MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. | Q34681455 | ||
| Occupancy and mechanism in antibody-mediated neutralization of animal viruses | Q34788252 | ||
| Dissection of antibody specificities induced by yellow fever vaccination | Q34789343 | ||
| Evidence for a Continuous Drift of the HIV-1 Species towards Higher Resistance to Neutralizing Antibodies over the Course of the Epidemic | Q34819651 | ||
| Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entry | Q34875765 | ||
| Isolate-Specific Differences in the Conformational Dynamics and Antigenicity of HIV-1 gp120 | Q34885869 | ||
| Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 | ||
| Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions | Q35006601 | ||
| Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes | Q35034268 | ||
| The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein | Q35069160 | ||
| Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes | Q35076711 | ||
| Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity | Q35101464 | ||
| A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins | Q35138111 | ||
| Structure and immune recognition of trimeric pre-fusion HIV-1 Env. | Q35142291 | ||
| Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement | Q35152094 | ||
| Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine | Q35206695 | ||
| Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera | Q35294150 | ||
| Intra-spike crosslinking overcomes antibody evasion by HIV-1 | Q35462906 | ||
| Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms | Q35531167 | ||
| Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. | Q35603504 | ||
| P433 | issue | 4 | |
| P921 | main subject | antibody | Q79460 |
| viral infectious disease | Q1928978 | ||
| vaccine development | Q27133094 | ||
| P304 | page(s) | 989-1010 | |
| P577 | publication date | 2016-10-26 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Microbiology and Molecular Biology Reviews | Q6839270 |
| P1476 | title | Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity | |
| P478 | volume | 80 |
| Q97566482 | A perspective on potential antibody-dependent enhancement of SARS-CoV-2 |
| Q59350545 | A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions |
| Q60225275 | An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus |
| Q63246516 | An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus |
| Q90059598 | Antibody Response against Cowpea Mosaic Viral Nanoparticles Improves In Situ Vaccine Efficacy in Ovarian Cancer |
| Q89555193 | Basic Amino Acid Substitution at Residue 367 of the Envelope Protein of Tembusu Virus Plays a Critical Role in Pathogenesis |
| Q59352713 | Blocking the Exit: CHIKV Neutralizing Antibodies Nip Viral Egress in the Bud |
| Q98884299 | Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19? |
| Q94589965 | Cell entry mechanisms of SARS-CoV-2 |
| Q95602418 | Coronaviruses pandemics: Can neutralizing antibodies help? |
| Q90861290 | De Novo Isolation & Affinity Maturation of yeast-displayed Virion-binding human fibronectin domains by flow cytometric screening against Virions |
| Q99575997 | Dengue mouse models for evaluating pathogenesis and countermeasures |
| Q47558158 | Development of Antibody Therapeutics against Flaviviruses |
| Q96302672 | Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality |
| Q62485447 | Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika |
| Q60300903 | Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth |
| Q97687005 | Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections |
| Q59358443 | Long-term stability of antibody responses elicited by Dengue virus envelope DIII-based DNA vaccines |
| Q33664416 | Modulation of Mycobacterium tuberculosis-specific humoral immune responses is associated with Strongyloides stercoralis co-infection |
| Q91928841 | Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice |
| Q104480403 | Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments |
| Q99343873 | SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors |
| Q96642743 | Serological Analysis of New York City COVID19 Convalescent Plasma Donors |
| Q99363854 | Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients |
| Q96824020 | Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population |
| Q98236105 | Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population |
| Q112076717 | The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease |
| Q59351678 | The Many Faces of a Dynamic Virion: Implications of Viral Breathing on Flavivirus Biology and Immunogenicity |
| Q47229433 | The Zika virus envelope protein glycan loop regulates virion antigenicity |
| Q47558217 | The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. |
| Q93149856 | Vaccines Against Dengue and West Viruses Nile in India: The Need of the Hour |
Search more.